Publication Name	World Journal of Hepatology
Manuscript ID	15818
Country	France

Received	2014-12-10 14:01
Peer-Review Started	2014-12-10 16:46
To Make the First Decision	2015-02-07 15:01
Return for Revision	2015-02-11 11:22
Revised	2015-03-15 02:09
Second Decision	2015-08-20 16:23
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2015-08-31 15:09
Articles in Press	2015-08-31 15:09
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-09-07 09:47
Publish the Manuscript Online	2015-09-15 18:11

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging
Manuscript Source	Invited Manuscript
All Author List	Mohamed Bouattour, Audrey Payancé and Johanna Wassermann
Funding Agency and Grant Number
Corresponding Author	Dr. Mohamed Bouattour, Department of Hepatology, Beaujon University Hospital (AP-HP - Paris 7 Diderot), 100 Boulevard du Général Leclerc, 92110 Clichy, France. mohamed.bouattour@aphp.fr
Key Words	Hepatocellular carcinoma; Antiangiogenic therapies; Sorafenib; Predictive biomarkers; Prognosis biomarkers; Functional imaging
Core Tip	The approval of sorafenib in advanced hepa-tocellular carcinoma is based on the positive results of two large randomized phase Ⅲ clinical trials. The inter- and intra-individual variability regarding tumor response and clinical outcome highlighted the unmet need of effective biomarkers of response. These biomarkers could be useful for monitoring treatment activity, detecting early resistance to treatment and identifying patients who would more likely benefit from treatment. An overview of prognostic/predictive biomarkers of sorafenib in hepatocellular carcinoma is discussed in this review.
Publish Date	2015-09-15 18:11
Citation	Bouattour M, Payancé A, Wassermann J. Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging. World J Hepatol 2015; 7(20): 2245-2263
URL	http://www.wjgnet.com/1948-5182/full/v7/i20/2245.htm
DOI	http://dx.doi.org/10.4254/wjh.v7.i20.2245

Full Article (PDF)	WJH-7-2245.pdf
Full Article (Word)	WJH-7-2245.doc
Manuscript File	15818-Review.doc
Answering Reviewers	15818-Answering reviewers.pdf
Audio Core Tip	15818-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	15818-Conflict-of-interest statement.pdf
Copyright License Agreement	15818-Copyright assignment.pdf
Peer-review Report	15818-Peer-review(s).pdf
Scientific Misconduct Check	15818-Scientific misconduct check.pdf
Scientific Editor Work List	15818-Scientific editor work list.pdf